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Traditionally, the advertising of prescription drugs through television has been
directed to medical professionals. Doctors and pharmacists act as the intermediary
between pharmaceutical companies and the ultimate consumers, the public. Re-
cently, pharmaceutical and media companies have challenged provisions in the
Food and Drug Act (FDA),1 which prohibit direct-to-consumer advertising
(DTCA) of drugs on television, as a violation of their freedom of expression.2 Me-
dia and pharmaceutical companies contend that their commercial interest is at a
competitive disadvantage to comparable American businesses since, unlike the lat-
ter, Canadian companies cannot sell advertising space to pharmaceutical companies
or advertise their brand to increase awareness of their drug directly to consumers.
The federal government, on the other hand, argues that the objective of the
restrictions on DTCA stems from the government’s need to protect public health
and to prevent Canadians from being misled by erroneous information. Addition-
ally, the legislature is hesitant to lift the current restrictions on drug advertising on
television due to the current situation in the U.S., where pharmaceutical advertising
has exorbitantly driven up healthcare costs.3 However, their objectives are aggra-
vated by their lower level of control over cross-border drug advertisements, which
stream on American cable networks into Canadian homes. If the ban on DTCA is
lifted in Canada, it is predicted that the pharmaceutical industry would spend ap-
proximately $500 million on pharmaceutical advertisements in the first year. How-
ever, it is also estimated to lead to at least $1.1 billion in extra drug sales in that
* J.D. Candidate 2011, University of Ottawa; M.Phil, 2009, University of Cambridge;
A.B., 2006, Dartmouth College. Special thanks to my family and friends for their
continual love and encouragement, Professors Monica Song and Kirsten Embree for
advising me, and my professors for inspiring me to write.
1 RSC 1985, c. F-27.
2 Canwest MediaWorks Inc. v. Canada (Minister of Health), 2008 FCA 207, 382 N.R.
365.
3 Barbara Mintzes, Steve Morgan & James M. Wright, “Twelve Years’ Experience with
Direct-to-Consumer Advertising of Prescription Drugs in Canada: A Cautionary Tale”,
online: (2009) 4:5 PLoS ONE e5699 <http://clinicaltrials.ploshubs.org/
article/info:doi/10.1371/journal.pone.0005699>.
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first year.4
The Supreme Court of Canada has consistently wrestled with the conflict be-
tween legislation designed to protect consumers’ health and the constitutional guar-
antee of the fundamental freedom of expression.5 This paper investigates the justi-
fication for the current regulatory framework for pharmaceutical advertising on
television. Aware that the provisions in the FDA are able to withstand Charter of
Rights and Freedoms6 (Charter) scrutiny, several possible policy initiations are
nevertheless proposed.
The paper is divided into five separate sections. Having first introduced
DTCA of pharmaceuticals on television in Section I, I will now turn to a more
comprehensive examination of DTCA in Canada in Section II. Next, I will fully
examine the nature of expression characterized in drug advertising in Section III,
before delving into the main argument of the paper, a Section One challenge Char-
ter challenge in Section IV. Finally, I conclude that the current prohibitions against
DTCA of drugs on television are justified and will provide a few recommendations
in Section V.
II. DTCA IN CANADA
The FDA currently enables the federal government to regulate prescription
drug advertising on television with the purpose of protecting public health and
safety.7 Restrictions on drug advertisements on television fall under section 3(1) of
the FDA which states that “no person shall advertise any food, drug, cosmetic or
device to the general public as a treatment, preventative or cure for any of the dis-
eases, disorders or abnormal physical states referred to in Schedule A.”8 More spe-
cifically, Schedule A contains 46 diseases, disorders or abnormal physical states,
for which all diseases listed in Schedule A require a medical practitioner’s inter-
vention to gain access to prescription drugs treating those illnesses.9
The restrictions were further broadened to cover all prescription drugs listed in
an additional appendix known as Schedule F.10 The rationale is that people who are
seriously ill from diseases set out in Schedule A, and who require prescription
drugs set out in Schedule F, may be vulnerable to the unscrupulous marketing of
prescription medicines.11 Therefore, the federal government has relied on doctors
and pharmacists to provide consumers with reliable unbiased information.
4 Women and Health Protection, “CanWest’s Charter Challenge on Prescription Drug
Advertising: A Citizens’ Guide” (2006) at 4, online: <http://www.whp-
apsf.ca/pdf/charter_challenge_en.pdf>.
5 Supra note 3.
6 Canadian Charter of Rights and Freedoms, Part I of the Constitution Act, 1982, being
Schedule B to the Canada Act 1982 (UK), 1982, c. 11.
7 Supra note 4 at 1.
8 Supra note 1, s. 3(1).
9 Ibid, Sch. A.
10 Ibid, Sch. F.
11 Supra note 4 at 1.
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The FDA defines advertising as “any representation by any means whatever
for the purpose of promoting directly or indirectly the sale or disposal of any food,
drug, cosmetic or device.”12 Canada’s current regulatory scheme permits two types
of pharmaceutical advertisements: help-seeking and reminder advertisements.
Help-seeking advertisements do not mention a specific brand, but discuss a condi-
tion and suggest viewers or readers to ask their doctors for more information. Re-
minder advertisements contain only the brand name and cannot include health
claims or hints about the product’s use, such as a listing of the drug’s medical
treatments and risks.13
In terms of regulation, Health Canada is the national regulatory authority for
DTCA. However, the ultimate responsibility for the enforcement of the FDA, in-
cluding violations of drug advertising on television, has been entrusted to three sep-
arate agencies:
1. The Code of Marketing Practices Committee of Rx&D, the public as-
sociation representing research-based pharmaceutical companies;
2. Advertising Standards Canada (ASC), an advertising industry associa-
tion; and,
3. The Pharmaceutical Advertising Advisory Board (PAAB), an indepen-
dent review agency.14
The Rx&D standardizes drug advertising on television by requiring its mem-
bers to follow its Code of Ethical Practices.15 The ASC reviews and pre-clears
prescription drug and non-prescription drug advertising on television.16 The
PAAB, in conjunction with the ASC, act as law enforcement for violations against
the FDA. If the agencies find an advertisement that is inconsistent with the legisla-
tion, the company is asked to withdraw the advertisement and/or replace it with
another that complies with the law.
Contraventions of pharmaceutical television advertisements are handled di-
rectly by Health Canada. Generally, the complainant receives a letter within 30
days acknowledging the complaint and notifying that the matter is currently being
investigated. However, a timeline is not provided, and the complainant is not con-
sulted during the investigation. It is unusual for a complainant to receive a letter
regarding the decision in less than six months after filing a complaint.17
Additionally, Health Canada’s Health Product and Food Branch Inspectorate
may employ “a wide array of enforcement mechanisms including fines, injunctions,
prosecution and imprisonment, forfeiture, public warning or advisory, and letters to
trade and regulated parties.”18
12 Supra note 1, s. 2.
13 Barbara Mintzes, What are the Public Health Implications? Direct-to-Consumer Ad-
vertising of Prescription Drugs in Canada (Toronto: Health Council of Canada, 2006)
at 7.
14 Ibid at 9.
15 Ibid.
16 Ibid.
17 Ibid at 11.
18 Ibid.
76   CANADIAN JOURNAL OF LAW AND TECHNOLOGY [9 C.J.L.T.]
Health Canada also considers a number of factors when determining enforce-
ment, including “risks to health and safety, the company’s compliance history, pre-
meditation, likelihood of recurrence, expected effectiveness, effects on public con-
fidence in Health Canada, and the department’s priorities and available
resources.”19 Unlike the United States Food and Drug Administration, Health Can-
ada has no personnel dedicated to the enforcement of drug advertising regula-
tions.20 This perhaps explains why penalties have not been imposed on any phar-
maceutical companies for illegal advertising activities since 1978.21
While DTCA is subject to strict regulatory limits in Canada and in most coun-
tries, the United States and New Zealand are the only two nations with legal DTCA
of pharmaceuticals on television. Their experiences serve as a useful comparator to
the situation in Canada, and will be used for analysis in the following section of
this paper.
(a) The Effect of Cross-Border Drug Advertising on Television
For the purposes of this paper, I will mainly examine the effect of cross-border
American prescription drug advertisements rather than New Zealand’s effect due to
its geographic proximity and likelihood of spill-over in Canada.
American pharmaceutical commercials are able to name the brand of the drug
and the drug’s targeted use as well as give specific details of the risks involved
when taking the medication. American drug advertisements on television may also
direct consumers to other sources of information such as websites or toll-free num-
bers. This is in contrast to Canada’s regulatory framework where drug advertise-
ments are only allowed to mention the name or the condition it treats, but are pro-
hibited from providing both.22
Canadians, through cable television, receive many of these prohibited adver-
tisements from American television stations. The cross-border effect has led to
roughly 53% of Canadians to believe that prescription drug advertising is legal,
even though it is restricted by the FDA.23 This had led many Canadians to believe
that DTCA is permitted in Canada and others to criticize that the restrictions on
DTCA is ineffective. Moreover, the spill-over of American drug advertisements
dilutes the federal government’s objective to protect Canadians. The American
Food and Drug Administration does not require the pre-clearance of drug advertise-
ments before they are released, thus leaving most American advertisements on tele-
vision unregulated.24 Arguably, the Canadian regulatory framework becomes inef-




21 Standing Committee on Health, Opening the Medicine Cabinet: First Report on Health
Aspects of Prescription Drugs (Ottawa: House of Commons, 2004) at 9.
22 Supra note 13 at 8.
23 “Ipsos-Reid Survey Shows Strong Public Support for Direct-to-Consumer Advertising
of Prescription Medications”, Canada NewsWire, News Release (31 January 2002).
24 Ibid.
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III. FREEDOM OF EXPRESSION
Critics of the current regulatory DTCA framework have challenged the restric-
tions as a limitation on freedom of expression. Though it is possible that other
Charter challenges can be made, a detailed discussion of all possible Charter chal-
lenges is beyond the scope of this paper. This section will describe the courts’ per-
spectives on commercial expression before delving into a constitutional analysis on
a potential violation of freedom of expression.
The guarantee of freedom of expression is set out in section 2(b) in the Char-
ter as follows: “freedom of thought, belief, opinion and expression, including free-
dom of the press and other media of communication.”25 To start, it is necessary to
define the term “expression” as it applies to pharmaceutical advertisements on tele-
vision. The expression characterized in advertisements is generally known as com-
mercial expression. Pure commercial expression’s primary purpose is to increase
profits.26 A claim against the federal prohibitions against DTCA of medications on
television may be challenged under commercial expression.27
The Supreme Court of Canada first addressed the issue of commercial expres-
sion under section 2(b) in the leading case, Ford v. Québec (Attorney General).28
The case involved challenges against the sole use of French in commercial adver-
tising. The Court discarded “the view that commercial expression serves no indivi-
dual or societal value in a free and democratic society [. . .] undeserving of any
constitutional protection.”29 Thus, the judgment cemented the idea that freedom of
expression was not confined to political expression but also extended to expression
made for commercial purposes.
According to Professor Hogg, an expert in constitutional law, commercial ex-
pression is guaranteed for two reasons. Firstly, commercial expression literally de-
rives from the definition of the word “expression” and as such, makes a contribu-
tion to the “marketplace of ideas.”30 Secondly, many intrinsic political, economic
and social ideas are inherent in commercial speech. Thus, commercial expression
including drug advertisements on television is constitutionally protected.
The Supreme Court of Canada, since the late 1980s, has consistently ruled that
commercial expression is an activity protected under section 2(b) of the Charter.
The main rationale for protecting commercial expression has been the reliance of a
free-market economy consisting of informed consumers, and thus, the protection of
the consumer.31 The Court has also granted considerable protection to expression
through section 2(b) of the Charter. This includes the protection of the right to
25 Supra note 6, s. 2(b).
26 Robert J. Sharpe, “Commercial Expression and the Charter” (1987) 37 UTLJ 229 at
230.
27 Supra note 2.
28 [1988] 2 S.C.R. 712, 54 D.L.R. (4th) 577.
29 Supra note 28 at para. 59.
30 Peter W. Hogg, Constitutional Law of Canada: Student Edition 2007 (Toronto: Cars-
well, 2007) at 418.
31 Keith Dubick, “Commercial Expression: A “Second-Class” Freedom?” (1996) 60 Sask
L Rev 91.
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receive and impart information,32 which arguably includes a consumer’s right of
access to health information from drug advertisements on television. This guarantee
could thus be invoked to challenge federal restrictions on DTCA on drug advertise-
ments on television given that the prohibitions limit the right of pharmaceutical
manufacturers to directly inform the public, which restricts the public’s access to
information about their drugs. Therefore, federal restrictions on DTCA of drugs on
television are vulnerable to a Charter challenge based on the freedom of expression
guarantee in section 2(b).
(a) Violation of Freedom of Expression
For a freedom of expression claim, the Supreme Court of Canada outlined a
two-step test from the landmark case on expression, Irwin Toy Ltd. v. Quebec
(Attorney General).33 To start, the court must question whether the plaintiff’s activ-
ity falls within the protective scope of section 2(b). Any activity which conveys or
attempts to convey meaning or expressive content falls within the protective scope
of 2(b) unless it is violent.34 By violent, the Supreme Court of Canada means phys-
ically aggressive-type of violence. Hence, threatening, silencing or intimidating
speech, because it is not actually physically violent, is still within the scope of sec-
tion 2(b).35
For commercial expression of DTCA of pharmaceuticals on television, the
courts would ask whether drug advertisements on television communicating di-
rectly to consumers could be classified as an activity which conveys or attempts to
convey meaning. As found in Ford v. Québec (Attorney General), commercial ex-
pression clearly falls within the protective realm of section 2(b).36 Based on the
court’s broad interpretation of the freedom of expression guarantee,37 DTCA of
medications on television would probably be found as a form of expression with
substantive informational content and within the scope of section 2(b).
The courts, in the second step of the Irwin Toy test, then ask whether the pur-
pose or effect of the challenged law is to restrict attempts to convey meaning. In
this case, the challenged law is the regulatory framework of DTCA in Canada. The
effect of the restrictions in the FDA prohibits pharmaceutical companies from pro-
ducing advertisements that convey meaning directly to consumers. Additionally,
Canadian media companies are prohibited from airing brand-name television adver-
tisements that communicate directly to the public without a medical professional as
an intermediary. The federal government, therefore, controls efforts to convey a
meaning such as drug advertisements by directly restricting the content. Thus, the
legislation entrenches upon the section 2(b) guarantee and a violation of freedom of
32 Rhonda R. Shirreff, “For Them to Know and You to Find Out: Challenging Restric-
tions on Direct-to-Consumer Advertising of Contraceptive Drugs and Devices” (2000)
58 UT Fac L Rev 121 at 138.
33 [1989] 1 S.C.R. 927, 58 D.L.R. (4th) 577 [Irwin Toy].
34 Ibid.
35 R v. Keegstra, [1990] 3 S.C.R. 697, [1991] 2 W.W.R. 1.
36 Supra note 28.
37 Supra note 33.
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speech is established.
IV. APPLYING THE OAKES TEST
Once a Charter violation has been established, the federal government bears
the onus to justify its restrictions pursuant to section one of the Charter. The courts
employ the test set out in R. v. Oakes38 to establish a whether a limitation is justi-
fied under section one.
For the Oakes test, the government must first demonstrate that the objective of
the legislation is “pressing and substantial” to warrant the restriction, in this case,
on freedom of expression. Afterwards, the courts will assess the means used to
override the constitutional right and whether the means used satisfy three propor-
tionality criteria. Primarily, there must be a rational connection between the reason
for the Charter override and the objective of the legislation. Second, the means
must minimally impair the right in question. And finally, the effects of the limiting
measure must be proportional to their objective. In general, a rule of thumb is that
the more deleterious the effects, the more important the objective must be.
(a) Is The Legislative Objective Pressing And Substantial?
The federal government may suggest three separate objectives as pressing and
substantial to warrant overriding freedom of expression of DTCA of pharmaceuti-
cals on television: in the interest of safety and public health, protecting Canadians
from misleading information, and reducing healthcare costs.
(i) Safety and Public Health
The broad objective of protecting the public’s health through restricting
DTCA of medications on television was first identified with the FDA in the case
Ciba-Geigy Canada Ltd. v. Apotex Inc.39 As Gonthier J. explains: 
Prescription drugs contain medicinal substances which, while beneficial in
small doses, can be harmful or even fatal to health in larger quantities. It is
then quite natural for society to limit access to such products as a means of
protecting the individual. The advisability of use is determined by a profes-
sional, the physician or in some cases the dentist, and distribution is the
responsibility of a specialized “merchant”, the pharmacist.40
For this reason, the federal government is justified in intervening between
consumers and pharmaceuticals, especially in the context of the media. The me-
dia’s widespread influence can greatly affect patient’s demand for dangerous pre-
scription drugs.
In R. v. Thomas Lipton Inc.,41 Lipton contravened section 3 of the FDA by
directly advertising its margarine in magazines as a preventative treatment for heart
disease, which is a disease listed in Schedule A. Given that margarine is readily
available without the need of a doctor’s consent, the danger was that consumers
38 [1986] 1 S.C.R. 103, 26 D.L.R. (4th) 200 [Oakes].
39 [1992] 3 S.C.R. 120, 95 D.L.R. (4th) 385.
40 Ibid at para. 103.
41 [1989] 26 C.P.R. (3d) 385, 51 C.C.C. (3d) 104 (Ont. Prov. Ct.).
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would buy vast amounts of margarine to medicate themselves rather than speaking
to a healthcare professional about their condition. The Ontario Superior Court ac-
cepted this as a genuine danger, given the magnitude and seriousness of heart dis-
ease. Likewise, the courts may also accept a similar argument that pharmaceutical
advertising to consumers directly on television may be a potential hazard to safety
and public health as consumers may self-diagnose themselves rather than seek
medical attention.
However, there is a notable difference between the facts in R. v. Thomas
Lipton Inc. and the restrictions prohibiting DTCA of drugs on television. Margarine
is readily available in supermarkets without needing a signed prescription from a
medical professional. Conversely, prescription medications require a doctor’s inter-
vention before a pharmacist may distribute the drug. The danger of allowing DTCA
of medications on television may not be as real of a threat as in R. v. Thomas Lipton
Inc. given that doctors and pharmacists still act as an intermediary between pre-
scription drugs and consumers.
Additionally, in the Supreme Court of Canada case, RJR-MacDonald Inc. v.
Canada (Attorney General),42 McLachlin J. mandated that the purpose of the legis-
lation must be “accurately and precisely defined” so that its importance may be
properly evaluated. Overstating the legislation’s objective, such as the case at hand
of protecting public health in general, may result in the FDA being declared uncon-
stitutional for its broad breadth.
(ii) Misleading Information
A stronger argument for the government would be that the DTCA restrictions
are justified as a means to protect the public from misleading information. A simi-
lar argument was proposed by the Crown in RJR-MacDonald Inc. v. Canada
(Attorney General).43 The Crown argued that tobacco companies were primarily
motivated by profit and thus commercial manipulation of the public to entice con-
sumers to try their products was a likely consequence. This objective was upheld
by the Supreme Court of Canada.
The federal government could make a similar argument that pharmaceutical
and media companies are motivated by profit and could easily influence the infor-
mation in their drug advertisements on television to lead the public to believe it is
targeted to a certain disease. For example, a Canadian television advertisement for
Diane-35 was found to have raised safety concerns about the promotion of its unap-
proved use as a contraceptive and lack of information about its increased risks of
blood clots.44 Diane-35 was only approved as a treatment for severe acne users and
not as a contraceptive in Canada. Yet, Berlex Canada Inc., the manufacturer, ran
reminder advertisements suggesting otherwise as a promotional marketing strategy
for the drug. Nevertheless, though commercial manipulation driven by profits is a
genuine fear, in RJR-MacDonald Inc. v. Canada (Attorney General), McLachlin,
Sopinka and Major JJ. decided that “motivation to profit is irrelevant to the deter-
mination of whether the government has established that the law is reasonable or
42 [1995] 3 S.C.R. 199, 127 D.L.R. (4th) 1.
43 Ibid.
44 Supra note 3.
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that it is justified as an infringement on freedom of expression.”45
(iii) Rising Healthcare Costs
The strongest argument the federal government can make in support for
DTCA restrictions on drug advertisements on television is that the prohibition min-
imizes healthcare costs. The government’s concern is that lifting the ban will inevi-
tably drive more consumers to request brand-name drugs seen on television from
their physicians more often than their non-advertised generic counterparts. This has
been the experience in the United States and is the main impetus to the govern-
ment’s stance on the FDA restrictions.46
Additionally, new studies have been showing the same American trend of in-
creased prescriptions of DTCA drugs occurring in Canada. In one Canadian study,
patient requests for DTCA prescription drugs influenced physicians’ prescribing
volume and choice. The results showed that doctors were pressured to fulfill the
patient’s demand for the DTCA drug and thus increased prescribing volume of that
drug.47 This confirms results from a 2002 survey of over 1500 doctors in which
67% reported feeling pressured to prescribe DTCA drugs.48 Given that the federal
government subsidizes the healthcare system, healthcare costs will inevitably rise
when more patients are asking for costlier medications rather than taking the less-
expensive but equally effective generic versions of the same drug. The issue of
whether cost-cutting objectives are pressing and substantial, such as the one at
hand, will be further discussed in the following section.
(b) Proportionality Analysis
Assuming that the federal government passes the first stage of the Oakes test,
the second stage of the Oakes test is called the proportionality step which is divided
into three separate parts.
(i) Is there a Rational Connection between the Legislative Objective and
the Legislation?
Assuming the objectives are found to be sufficiently pressing and substantial,
the onus is on the federal government to show whether the government’s restric-
tions on drug advertising on television are rationally connected to the recognized
45 Supra note 42 at para. 171.
46 Barbara Mintzes et al, “Influence of direct to consumer pharmaceutical advertising and
patients’ request on prescribing decisions: two site cross sectional survey” (2002) 324
Brit Med J 278.
47 Barbara Mintzes et al, An assessment of the health system impact of direct-to-consumer
advertising of prescription medicines (DTCA). Volume IV: pills, persuasion and public
health policies. Report of an expert survey on direct-to-consumer advertising of pre-
scription drugs in Canada, the United States and New Zealand (Vancouver: University
of British Columbia Health Policy Research Unit, 2001).
48 Carmela DeLuca, Direct to consumer advertising of prescription medicines: assessing
the impact of consumer directed drug advertisement and the legality of current prohibi-
tions (Toronto: University of Toronto Health Law and Policy Group, 2005).
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objective.
Working in the government’s favour is the courts’ position to give deference
to the legislature when analyzing policy objectives. As stated in JTI-MacDonald
Corp. c. Canada (Procureure générale) regarding complex policy choices: “effec-
tive answers to complex social problems [. . .] may not be simple or evident. There
may be room for debate about what will work and what will not, and the outcome
may not be scientifically measurable. Parliament’s decision as to what means to
adopt should be accorded considerable deference in such cases.”49 Given that the
objectives behind the restrictions on DTCA of pharmaceuticals on television are
policy-driven, the courts will likely defer to the government.
(A) Safety and Public Health
The first objective the federal government may propose is that the prohibition
on advertising prescription drugs to consumers directly on television is warranted
because of public safety and public health concerns. The rationale behind this ob-
jective is that prescription drugs are more toxic than over-the-counter drugs and
thus consumers must go to an informed medical professional for more information.
The federal government is concerned that individuals experiencing illnesses which
require medical attention will diagnose themselves and manage their conditions
with drugs advertised on television without full information.
A corollary is that more heavily advertised drugs tend to be newer on the mar-
ket, and given their relatively new age, less information is readily available to the
public.50 The danger is that approximately 20% of drugs that are recent in the mar-
ketplace are withdrawn from the marketplace altogether or have new black box
warnings on its product pamphlet due to serious safety concerns found after-
wards.51 Additionally, evidence from a study conducted on reminder advertise-
ments in Canada showed that many heavily-advertised drugs were subject to regu-
latory warnings of serious risks.52 The danger is that if the restrictions are lifted it
will prompt consumers to readily take brand-name drugs that are relatively more
dangerous than generic alternatives. Thus, there is a serious public health concern
that is rationally connected to consumers seeking medical advice from a medical
professional rather than relying on advertisements seen on television.
With respect to public safety, the Supreme Court of Canada commented in
Rocket v. Royal College of Dental Surgeons (Ontario) that: 
As non-specialists, [the public] would lack the ability to evaluate competing
claims as to the quality of different dentists . . . The consuming public
would thus be far more vulnerable to unregulated advertising from dental
professions than it would be to unregulated advertising from manufacturers
or suppliers of many other, more standardized, goods or services. The fact
that the provincial legislature here acted to protect a vulnerable group ar-
49 2007 S.C.C. 30, [2007] 2 S.C.R. 610, 281 D.L.R. (4th) 589 at para. 41.
50 Edward A.M. Gale, “Lessons from the glitazones: a story of drug development” (2001)
357 The Lancet 1870.
51 Karen E. Lasser et al, “Timing of new black box warnings and withdrawals for pre-
scription medications” (2002) 287 JAMA 2215.
52 Supra note 3.
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gues in favour of viewing its attempted compromise with some deference.53
Likewise, restricting consumers’ direct access to information from drug adver-
tisements on television may be rationally connected to protecting the public from
potentially dangerous medications given the public’s inability to evaluate compet-
ing claims from different drugs. As such, there is a rational connection between
mandating that consumers seek more information from a medical professional and
protecting public health.
A mitigating factor, nevertheless, is that regardless of whether potentially dan-
gerous drugs are advertised directly to the public, consumers must still receive a
doctor’s consent for the pharmacist to prescribe the drug. The public must still
bring up their request for the drug to their medical professional and the medical
professional is under oath to provide accurate factual information to the patient
about the medication. Therefore, if the government was concerned with protecting
public safety, arguably a more effective though drastic solution would be prohibit-
ing the dangerous drugs from the marketplace altogether.
Arguably, it is also unreasonable for the federal government to advise doctors
to prescribe a drug cautiously because of its serious health risks, and then ignore
the effects of persuasive advertisements on television that make the same medica-
tion look safe to use. Most pharmaceutical advertisements on television downplay
safety information.54 Coupled with evidence that physicians are more likely to pre-
scribe advertised drugs requested by patients, this suggests that even with a medical
professional acting as an intermediary, there is no guarantee that the viewer is pro-
tected. Thus, the connection between advertising drugs directly to the public and
endangering public health is tenuous at best given that the dangerous medications
in question are still available in the marketplace and doctors will readily prescribe
them even with the current DTCA restrictions in place.
(B) Misleading Information
The second objective that the federal government may propose is that the
DTCA restrictions on pharmaceuticals on television are warranted because they
prevent consumers from receiving misleading information. The government’s posi-
tion stems from conclusions made in the Committee on Health’s report: “Opening
the Medicine Cabinet: First Report on Health Aspects of Prescription Drugs.” After
months of research and hearings, the Committee on Health concluded that Canada
should continue to limit DTCA of pharmaceuticals since lifting the restrictions will
not result in accurate, unbiased information for consumers.55
However, this objective is unlikely to succeed. The courts have refused to use
the standard of the “uninformed and naı̈ve” person.56 People are naturally critical,
and thus do not need restrictive rules to protect them from advertising. Addition-
ally, since the internet is highly prevalent in our culture today, the standard of the
53 [1990] 2 S.C.R. 232, 71 D.L.R. (4th) 68 at para. 35.
54 Joel Lexchin & Barbara Mintzes, “Direct-to-Consumer Advertising of Prescription
Drugs: The Evidence Says No” (2002) Journal of Public Policy & Marketing 194.
55 Supra note 21 at 10.
56 Supra note 42.
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uninformed and naı̈ve consumer should be used tentatively. It is possible that with
access to the internet, almost anyone can obtain information on a certain drug trial
or the risks and complications of a brand-name drug. Therefore, the federal govern-
ment cannot use the most oblivious consumer as the benchmark onto which a con-
stitutional analysis will be applied.
Furthermore, even in the event when a consumer is misled over a certain drug,
the consumer must still visit a medical professional before receiving a prescription
drug. Most prescription drugs cannot be administered without a doctor’s note. Any
potential brand-name drug user would have to first consult with a doctor who
would likely explain potential risks and dangers and thus clear up any misunder-
standing the consumer may have. Thus, by stating that restrictions on DTCA drug
advertisements on television are needed to prevent consumers from being misled by
pharmaceutical and media companies is perplexing.
Assuming that medical professionals are commercially independent from
pharmaceutical profits, doctors and pharmacists would give unbiased information
and advice about the drug to their patients. However, this view may be negated by
the event when medical professionals are given benefits and even fees when pro-
moting a certain brand-name drug. In this way, even if the government may protect
consumers from newly advertised medications, it may still not completely protect
the public since doctors may still prescribe these drugs for profit. Another minor
point is that physicians may be swayed by a patient’s demand for a particular drug
in an effort to maintain or increase their client base.
Another mitigating factor is that American television drug advertisements are
filtered into Canada and thus are not privy to FDA restrictions. Researchers found
that cross-border advertising from the United States increased prescribing of a min-
imally effective drug with a poor safety profile57 and subsequently the drug was
withdrawn from the marketplace.58 This, arguably, leads to an ineffective Canadian
regulatory framework since the objective of the restrictions can be circumvented by
companies who have an American presence. Thus, the rational connection of re-
stricting DTCA to protect Canadians from being misled is tenuous at best.
(C) Rising Healthcare Costs
The strongest objective that the federal government may propose is that re-
strictions are warranted since advertising drugs directly to consumers will drive an
increase in healthcare costs. The assumption is that consumers will ask for brand-
name drugs rather than their less expensive generic counterparts, which will in turn
promote more visits to the doctor thereby burdening federal resources.59 Both
57 B.W. Evans et al, “Tegaserod for the treatment of irritable bowel syndrome and chronic
constipation”, (Review) online: (2009) 4 Cochrane Database System Reviews
<http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD003960/frame.html>.
58 US Department of Health and Human Services, “Zelnorm (tegaserod maleate) Informa-
tion” (30 April 2009) online: U.S. Food and Drug Administration
<http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor
PatientsandProviders/ucm103223.htm>.
59 Canadian Pharmacists Association, “Position Statement on Direct-to-Consumer Adver-
tising (DTCA)” (2001) online:
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Health Canada and the House of Commons Standing Committee on Health argue
that because of the genuine concern of rising healthcare costs, the federal govern-
ment should continue to limit DTCA.60
Conversely, proponents for lifting DTCA restrictions argue that it is possible
that DTCA of drug advertisements on television may actually reduce healthcare
spending in the long run. If advertisements are allowed to list the symptoms of
certain conditions, an ensuing visit to the doctor could mean an early diagnosis of a
disease. Arguably, treatment of that same illness at a later stage would be more
expensive. However, there is no documented evidence for this. Nevertheless, there
has been documented evidence that removing DTCA restrictions increases health-
care costs. A study comparing French-speaking and English-speaking Canadian re-
sidents showed that DTCA advertising leads to higher healthcare costs due to in-
creased prescribing of a brand-name drug.61 Therefore, the federal government has
evidence proving a rational connection between reducing healthcare spending and
restrictions on DTCA.
Notably, the Supreme Court of Canada suggests that a cost-saving objective
may indeed be a justifiable means of limiting a Charter right such as freedom of
expression. In New Brunswick (Minister of Health & Community Services) v. G.
(J.),62 the Supreme Court justified a breach of a Charter right by articulating the
importance of restricting government spending. Professor Peter Hogg, a leading
constitutional law expert, proposes that when the cost is excessive, the restriction of
a Charter right may be permitted.63
(ii) Is the Legislation Minimally Impairing to the Right in Question?
At the next step of the proportionality analysis, the court considers whether the
impugned legislation, the restrictions on DTCA prohibiting pharmaceutical adver-
tising on television, minimally impairs freedom of expression. This requires an ex-
amination whether the federal government has considered alternatives and less im-
pairing means to achieve the same objective.64
If the government can show evidence that a less restrictive regime has proven
to be unsuccessful in achieving the objective, the justification will be established.
For example, in the dissent of RJR-MacDonald Inc. v. Canada (Attorney General),
the four dissenting judges found evidence that the current advertising regime of
tobacco products was the result of an intensive twenty-year period of experimenta-
tion with less intrusive measures.65 Accordingly, the dissenting judges would have
<http://www.pharmacists.ca/content/about_cpha/Who_We_Are/Policy_Position/pdf/dtca.pdf>.
60 Supra note 21.
61 Michael R. Law, Sumit R. Majumdar & Stephen B. Soumerai, “Effect of illicit direct to
consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: con-
trolled longitudinal study” (2008) 337 Brit Med J 550.
62 [1999] 3 S.C.R. 46, 177 D.L.R. (4th) 124.
63 Peter W. Hogg, Constitutional Law of Canada, 2001 Student Edition (Toronto: Cars-
well, 2001) at 755.
64 Supra note 42 at 352.
65 Supra note 42 at 307.
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upheld the prohibitive legislation.
In the case at hand, restrictions on DTCA of drug advertisements in the media
began in 1949,66 and over the years, the regulatory framework of DTCA has been
narrowed. Thus far, drug advertisements have been prohibited from advertising the
name of the drug in conjunction with their treatment. Less restrictive measures
have never been in place, but rather, more diseases and illnesses have been added
to Schedule A making the current regime more restrictive than in the past. The
federal government can argue that a less restrictive regime has been ineffective.
On several occasions, the courts have found that legislation restricting adver-
tising failed the minimal impairment stage. For example, the Supreme Court of
Canada held in Ford v. Québec (Attorney General) that the legislation violated sec-
tion 2(b) and failed the test of minimal impairment.67 Likewise, the Supreme Court
of Canada decided in Rocket v. Royal College of Dental Surgeons (Ontario)68 that
the objective could be maintained with less restrictive advertising prohibitions. Fur-
thermore, in RJR-MacDonald Inc. v. Canada (Attorney General),69 the majority of
the Supreme Court held that the total ban on tobacco advertising failed because it
did not minimally impair freedom of expression. To succeed, the government
would need to demonstrate that a total ban would be the only means to achieve its
objective. Since the government did not produce evidence suggesting otherwise,
the legislation failed this stage of the analysis.
In a DTCA challenge, the federal government would have to show evidence
defending its policy choice. It would have to demonstrate that other less impairing
methods to freedom of expression cannot achieve the same objective. Other less
intrusive methods such as unambiguous warnings on advertisements, mandatory
pre-clearance of all prescription drugs, and mandatory waiting times between drug
approval and campaign launch may be considered less impairing than the current
regulatory framework. However, there is no social science evidence demonstrating
that either of these methods would achieve the government’s objective.
In terms of burden of proof, a complete ban on a form of expression is more
difficult to justify than a partial ban. Arguably, the case at hand is a partial ban
since advertising to consumers is still allowed but is mediated by medical profes-
sionals. A complete ban on advertising to consumers would be a complete prohibi-
tion of drug advertising in any media outlet. Given that over the years, the federal
government has constricted DTCA of pharmaceuticals on television, it is highly
likely that the courts will view this as the federal government experimenting with
less intrusive measures. The current regulatory framework is the result of years of
testing measures that were found to be inadequate to meet the government’s objec-
tive. Only the current regulatory framework, therefore, can meet the government’s
objective. Therefore, it is highly likely that the legislation will pass the minimal
impairment test.
66 Judy Z. Segal, “‘Compliance’ to ‘Concordance’: A Critical View” (2007) 28 Journal of
Medical Humanities 81 at 90, online:
<http://www.springerlink.com/content/ht44782548171533/>.
67 Supra note 28.
68 [1990] 2 S.C.R. 232, 71 D.L.R. (4th) 68.
69 Supra note 42.
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(iii) Is there Proportionality between the Limits on Expression and the
Objective?
Once the legislation passes the minimal impairment test, the courts consider
the “sufficiently important” objective of the legislation against its potentially dele-
terious effects. The objectives of prohibiting DTCA of pharmaceuticals on televi-
sion are aimed at protecting public safety and public health, preventing the public
from being misled, and preventing an increase in healthcare spending. These objec-
tives ultimately outweigh the deleterious effects of restricting DTCA of
pharmaceuticals on television.
Relevant caselaw on freedom of expression suggests that this stage of the
Oakes test is dependent on the nature of the expression. In Thomson Newspapers
Co. v. Canada (Attorney General), at issue was the publication of election polls
close to the date of the election.70 The nature of expression in Thomson
Newspapers Co. v. Canada (Attorney General) was political and was found to vio-
late the core of the expression guarantee. Additionally, in RJR-MacDonald Inc. v.
Canada (Attorney General), the dissenting judges found that tobacco advertising
was motivated by profits.71 The government produced ample evidence linking the
sale of cigarettes to the decline in health of cigarette smokers. The judges ulti-
mately decided that the destructive effects of tobacco advertising and the subse-
quent objective of protecting public health prevailed over the intrusive effects of
violating the tobacco companies’ right to freedom of expression.72
In terms of DTCA of pharmaceuticals on television, the courts will take into
account the nature of the expression. As characterized earlier, the expression in
DTCA of pharmaceuticals on television is commercial. Unlike the expression in
Thomson Newspapers Co. v. Canada (Attorney General), commercial expression is
not entitled to the same constitutional protection as political expression.73 Similar
to tobacco advertising in RJR-MacDonald Inc. v. Canada (Attorney General), phar-
maceutical advertising on television is profit-oriented.74 The motive behind the
promotion of drugs is to increase brand awareness in the marketplace which will
ultimately increase sales. Both tobacco advertising and pharmaceutical advertising
are forms of commercial expression. In JTI-MacDonald Corp. c. Canada
(Procureure générale), the Supreme Court observed that “the prohibited speech [of
advertising] is of low value. Information about tobacco products and the character-
istics of brands may have some value to the consumer who is already addicted to
tobacco. But it is not too great.”75 Thus, given the similarity of drug advertising to
tobacco advertising, it is highly likely that the courts will find drug advertising to
be of low-value and thus not afforded as much constitutional protection as political
expression.
70 [1998] 1 S.C.R. 877, 159 D.L.R. (4th) 385 at 890.
71 Supra note 42.
72 Ibid.
73 Supra note 33.
74 Supra note 42.
75 Supra note 49 at para. 94.
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Regardless of the nature of expression, the Supreme Court has maintained that
all forms of expression, unless violent, are constitutionally protected: “whether po-
litical, religious, artistic or commercial, freedom of expression should not be sup-
pressed except where urgent and compelling reasons exist and then only to the ex-
tent and for the time necessary for the protection of the community.”76 Therefore,
even though pharmaceutical advertising on television is likely to be found to be of
low-value, the courts will not strike down restrictions on DTCA without properly
weighing the deleterious effects against the objectives.
One deleterious effect of the restrictions is the inability of consumers to access
healthcare information pertinent to their healthcare choices. Proponents for a
broader regulatory framework argue that DTCA of pharmaceuticals on television
will likely lead to increased patient empowerment and autonomy through greater
access to information. Direct drug advertising on television imparts more informa-
tion to the public about available medications on the marketplace, thereby educat-
ing consumers of their choices.
However, the extent to which DTCA provides a public service by educating
the public is dependent on the quality of content in the drug advertisements. Also,
the educational component of the advertisements is reliant upon the pharmaceutical
companies’ desire to release accurate and impartial information. However, studies
from both New Zealand and the United States, the only two countries that currently
allow DTCA of pharmaceuticals on television, have consistently demonstrated poor
quality of content.77 Information about likelihood of success, other options and
costs of treatment were often absent from drug commercials.78 Arguably, even if
the restrictions are lifted, consumers are still not guaranteed that they will be re-
ceiving needed information from pharmaceutical companies.
Another deleterious effect of the restrictions on drug advertisements on televi-
sion is the possibility for confusion from American advertisements. Advertisements
originating from the United States are not privy to Canadian regulations and thus
remain largely unregulated. There is currently an overflow of prescription drug tel-
evision commercials into Canada from the United States. Given this, it is probable
that the Canadian public will be misinformed about the brand-name drug promoted
in American advertisements. Health Canada may counteract this effect by allowing
pharmaceuticals to make standardized informative drug commercials. In this way,
Canadian DTCA would provide a uniform unbiased informative outlet to the
public.
An additional deleterious effect of DTCA restrictions is improved awareness
and usage of medications. Studies have shown that disease awareness or drug
awareness, effects of DTCA pharmaceutical advertising, lead to increased discus-
sions with a doctor for specific conditions and illnesses.79 Notably, these effects are
widespread among various socioeconomic groups. This is particular important es-
pecially among patients of low socioeconomic status, who are arguably often not
76 Supra note 33.
77 Supra note 54.
78 Supra note 4 at 4.
79 Abihilasha Mehta & Scott C. Purvis, “Consumer Response to Prescription Drug Adver-
tising” (2003) 43 Journal of Advertising Research 194 at 194.
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reached through public health campaigns.80 Proponents for DTCA in Canada argue
that the federal government should lift the restrictions in order to better serve vul-
nerable groups who are more likely to watch cable television than participate in
mass public health initiatives. However, critics argue that the socioeconomic
groups that are “likely to benefit” are mostly of low-income or are classified as the
working poor. Arguably, these groups will probably be unlikely to afford the more
expensive cable television notwithstanding the time to watch cable television while
managing multiple jobs.
Finally, another deleterious effect is that the knowledge obtained from phar-
maceutical advertisements may lead to improved public health by increasing appro-
priate consultations with doctors for undiagnosed health conditions. As patients be-
come more empowered with more information, they will be more willing to take
part in managing their illnesses in consultation with their doctor prompting greater
satisfaction in the healthcare system.81 Greater knowledge of a certain drug also
leads to better patient involvement in treatment plans.82 However, research shows
that DTCA does little to make the public aware of all drugs available to the market-
place given that 40% of annual DTCA spending is devoted to only ten drugs.83
Provided that only a small subset of prescription drugs are advertised, DTCA of
pharmaceuticals on television will only increase appropriate consultations for only
those limited number of drugs.
(c) Assessing Objectives with Deleterious Effects
The federal government’s perspective assumes that the public cannot distin-
guish between factual and false claims. As such, the federal government has placed
restrictions on pharmaceutical advertising on television to prevent the public from
being misled in the name of preventing commercial manipulation. Furthermore,
there is ample evidence demonstrating that many of the medications advertised on
television have serious health warnings or are taken off the market altogether.84
Thus, another objective of the government is to protect Canadians from dangerous
drugs — a policy-oriented public health goal. Both objectives take for granted the
standard of the average Canadian as an uninformed consumer. Since this consumer
is incapable of viewing of viewing prescription drug advertisements on television
critically and analytically, the federal government must therefore protect this vul-
nerable group.
However, both government objectives are mitigated by today’s current tech-
nology. Historically, it was difficult to access healthcare information unless pa-
tients visit their doctors. However, with today’s technological advances such as the
80 Elizabeth Murray et al, “Direct-to-Consumer Advertising: Public Perceptions of Its Ef-
fects on Health Behaviours, Health care, and the Doctor-Patient Relationship” (2004)
17 Journal of the American Board of Family Practice 6 at 13.
81 Supra note 4.
82 Ethan Cumbler et al, “Lack of patient knowledge regarding hospital medications”
(2010) 5 Journal of Hospital Medications 83.
83 Supra note 12.
84 Supra note 3.
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internet, patients have greater access to health information.85 Therefore, today’s
patients are more informed and less deferential to their healthcare providers.86 This
is illustrated in a growing movement towards individual autonomy, as epitomized
in current informed consent laws to medical treatment. Given that both of these
objectives are mitigated, it is likely then that the deleterious effects of restricting
DTCA of pharmaceuticals on television outweigh both objectives.
The federal government’s strongest case is championing the objective of re-
ducing healthcare costs. Lifting the restrictions on DTCA of pharmaceuticals on
television will ultimately drive an increase in healthcare spending. Pharmaceutical
advertising on television is the largest growing market in television advertising.
Despite the illegality of DTCA in Canada, over $90 million was spent on branded
advertisements between 1995 to 2006.87 Results from a comparative study between
DTCA and non-DTCA environments show that increased DTCA advertising leads
to more requests for advertised medicines and more prescriptions for them.88 The
government’s concern is that if DTCA restrictions on pharmaceutical advertise-
ments on television are lifted, conversations between patients and doctors will
likely end with a prescription for a brand-name drug rather than a generic less-
known pharmaceutical equivalent. There is recent strong evidence linking health-
care costs with DTCA of pharmaceuticals on television.89 Additionally, the Su-
preme Court has consistently deferred to the legislature when assessing cost-cutting
objectives.90 In all likelihood, the restrictions on DTCA of drugs on television will
likely stand since the objective greatly outweighs the deleterious effects.
V. CONCLUSION
Evidence shows that DTCA of pharmaceuticals on television can and does
cause harm. Firstly, most drug advertisements on television are promoting medica-
tions with severe health warnings and, in most cases, are later taken off the market.
Secondly, most DTCA drug advertisements do not contain quality unbiased infor-
mation. Most importantly, there is a direct correlation between drug advertising on
television and healthcare costs. The federal government’s strongest argument
would be justifying the current regulatory framework under FDA as a means to
lower these expenditures. As such, the restrictions on DTCA of prescription drugs
on television would most likely withstand a Charter challenge given that the Su-
preme Court has deferred to the legislature in the past when analyzing cost-cutting
objectives. The restrictions on DTCA of pharmaceuticals on television likely re-
main valid.
85 Colin Meek, Direct-to-Consumer Advertising of Prescription Medicines: A Review of
International Policy and Evidence (London: Royal Pharmaceutical Society of Great
Britain, 2001) at 5.
86 Reshma Jagsi, “Conflicts of Interest and the Physician-Patient Relationship in the Era
of Direct-to-Patient Advertising” (2007) 25 Journal of Clinical Oncology 902 at 904.
87 Supra note 3.
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Nevertheless, there is undoubtedly a need for better enforcement with Can-
ada’s current regulatory framework. A recommendation would be to include active
monitoring and eliminate conflicts within the FDA. To start, the federal govern-
ment should adopt the Committee on Health’s recommendation to eliminate re-
minder advertising since “any direct-to-consumer advertising, including reminder
ads, could contribute to increased or inappropriate drug consumption.”91 Addition-
ally, the federal government should review Canada’s approach to cross-border tele-
vision broadcasting. Currently, American drug advertisements containing illegal
and often misleading content are allowed to be aired in Canada. This activity is
inconsistent with the government’s objectives. Hopefully, in this way, current poli-
cies will provide more of the type of accurate unbiased information Canadians need
about prescription drugs. 
91 Supra note 21.
